Aberrant Erythroblast Detection for Non-Invasive Bone Marrow Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic approaches for cancer, particularly in detecting bone metastasis and assessing tumor aggressiveness, are complex, inefficient, and often fail to detect early-stage cancer effectively, relying on invasive methods and limited by the recognition of systemic spread and metastasis.
Innovation Solution
A method involving the analysis of aberrant erythroblasts in bodily fluid samples, including determining their molecular and phenotypical characteristics, such as ploidy, nuclear morphology, and expression of markers like CD71, GPA, and vimentin, to reflect bone marrow conditions and predict bone marrow damage and tumor invasiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional bone marrow aspiration is used for detecting bone marrow disorders and tumor staging, then diagnostic reliability is improved, but patient discomfort and invasiveness increase
Solution Approach 1:
The patent uses circulating erythroblasts as an intermediary marker to indirectly assess bone marrow status. Instead of directly sampling bone marrow, the method detects erythroblasts in peripheral blood that reflect bone marrow conditions, thereby providing diagnostic information without the invasiveness of bone marrow aspiration
Solution Approach 2:
The patent creates a liquid biopsy copy of bone marrow information by analyzing circulating erythroblasts in peripheral blood. These circulating cells serve as a surrogate or copy that contains diagnostic information about bone marrow status, allowing non-invasive detection of bone marrow disorders and tumor involvement
2Reliability
If current diagnostic methods are used for early cancer detection, then systemic spread recognition is limited, but detection sensitivity for early-stage cancer worsens
Solution Approach 1:
The patent performs preliminary detection of bone marrow involvement by analyzing circulating erythroblasts before systemic metastasis becomes apparent. This early assessment of bone marrow status provides advance information about tumor aggressiveness and potential metastatic spread, enabling earlier intervention
Solution Approach 2:
The patent replaces traditional mechanical/invasive diagnostic methods (bone marrow aspiration, biopsy) with a liquid biopsy approach using circulating erythroblasts. This substitution enables detection of bone marrow status and early cancer signs without physical intrusion, improving both sensitivity and patient comfort
3Measurement precision
If comprehensive tumor aggressiveness assessment is performed using traditional methods, then diagnostic accuracy is improved, but diagnostic complexity and time increase
Solution Approach 1:
The patent extracts the essential diagnostic information about bone marrow status and tumor aggressiveness from complex traditional diagnostic procedures by focusing specifically on circulating erythroblasts. This extraction isolates the key diagnostic marker, simplifying the overall diagnostic process while maintaining assessment accuracy
Solution Approach 2:
The patent makes the circulating erythroblast analysis serve multiple diagnostic functions simultaneously: assessing bone marrow status, detecting early cancer signs, evaluating tumor aggressiveness, and monitoring disease progression. This multi-functionality consolidates multiple diagnostic objectives into a single analytical approach, reducing overall diagnostic complexity
Data Source
AI summary
The present invention relates to a method for detecting, diagnosing, monitoring or prognosticating a pathologic status in a subject’s bone marrow including at least the step of determining the presence of aberrant erythroblasts in a subject’s bodily fluid sample. Also envisaged is the use of aberrant erythroblasts as a marker for diagnosing, detecting, monitoring or prognosticating a pathologic status in a subject’s bone marrow, as well as a composition for diagnosing, detecting, monitoring or prognosticating a pathologic status in a subject’s bone marrow, including means for the determination of the presence of (i) CD71 and/or GPA, (ii) CD45, (iii) nucleic acids of rare circulating cells and at least one of (iv) or (v): (iv) EpCam and (v) vimentin, in a subject’s sample.